It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
Barilla vs. Pastificio Fazion, Supreme Court (Corte Suprema di Cassazione), 30 December 2011
-
Specialized IP Courts in China: One Giant Step?
-
Brazil: Animal Health and Patent Litigation
-
Commercial courts of Barcelona go one step further towards specialisation
-
Even more on pemetrexed
-
Barcelona Patent Court judgment on claims comprising technical and non-technical features
-
Patent case: Pemetrexed, Austria
-
Belgium, Case Law, Chemical Engineering, Enforcement, Equivalents, Extent of Protection, Injunction, Scope of protection
Merck v. Teva, Commercial Court Antwerp (Rechtbank van Koophandel te Antwerpen), 20 October 2009
-
UPC: More information about access to new CMS
-
THE DISMAL HISTORY OF COMPULSORY LICENCES IN INDIA